Connie Wierman is New Theorem Clinical Research Vice President of Biopharmaceutical Development

(King of Prussia, PA; May 7, 2013) — Connie Wierman, a seasoned executive with more than 25 years of biopharmaceutical experience, has been named vice president of biopharmaceutical development for Theorem Clinical Research. She leads the company's oncology therapeutic focus for the biopharmaceutical business unit.

"We're building a team of top industry professionals at all levels of the Theorem organization and Connie fits right into that vision," said Theorem President and CEO John Potthoff. "She has built an impressive career with an emphasis on the global clinical development of oncology therapies. We count on her to provide an excellent operational environment and successful outcomes for our clients."

Wierman held a number of executive posts at leading industry firms prior to joining Theorem, including vice president of clinical development in oncology for INC Research. She was also responsible for developing and leading a team of medical science liaisons in 12 territories across the U.S. for ILEX (now Sanofi-Aventis) to support the research and educational goals for oncology agents under development and those recently launched.

Wierman received both her bachelor's degree in medical microbiology and her MBA in marketing from the University of Wisconsin.

"Theorem has given me the opportunity to put some of my thoughts and ideas into actionable programs to help smooth and streamline the clinical trials process," Wierman said. "I'm very excited about the work we're doing and some of the advances we hope to be able to make in the future."

About Theorem Clinical Research

Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's leading pharmaceutical, biotech and medical device companies. A leader in medical device and drug-device combination trials in addition to a notable capability in pharmaceuticals and biologics, Theorem has deep expertise in a broad range of therapeutic areas and in all phases of development. Some of the industry's top scientists and most advanced clinical analytics capabilities help ensure smooth-running, successful trials. For a full-service, right-size global research partner, don't think twice. THINK THEOREM.

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.